Aisling Capital — 2018 Investments

3 investments dated 2018 · listed companies and verified rows first · show all

Eidos Therapeuticseidostx.com 𝕏Series B · Apr 2018 · $64MAcquired

A digital health resource platform providing medical professionals with educational information and clinical resources about transthyretin amyloid cardiomyopathy (ATTR-CM) and related cardiac and neurological conditions.

BiotechDigital HealthHealthtechSan Francisco, US

NEIL KUMAR(Executive Officer, Director)JONATHAN FOX(Executive Officer)UMA SINHA(Executive Officer)CHRISTINE SIU(Executive Officer)HOYOUNG HUH(Director)ERIC AGUIAR(Director)

Board seatEric Aguiar· per SEC Form D

Co-investorsForesite Capital Hercules Capital, Inc.RA Capital Viking Global Viking Global Investors

MEI Pharmameipharma.com in 𝕏May 2018

Lite Strategy, Inc.

BiotechCrypto & Web3FintechHealthtechSan Diego, US

David M. Urso(Executive Officer)inDaniel P. Gold(Executive Officer, Director)Brian G. Drazba(Executive Officer)inMr. File(Chief Executive Officer & Board Member (former CFO))Justin (Jay) File(CEO, CFO)inKevan E. Clemens(Director)

Co-investors3B Future Health Fund GSR New Enterprise Associates (NEA)Primitive Ventures Amzak Health Biotechnology Value Fund +1 more

Nabriva Therapeuticsnabriva.comJul 2018

BiotechDublin 1

Jennifer Schranz(Executive Officer)Axel Bolte(Director)Gary Sender(Executive Officer)Theodore Schroeder(Executive Officer, Director)Robert Crotty(Executive Officer)Colin Broom(Director)

Co-investorsEcoR1 Capital Frazier Life Sciences Longitude Capital MESA VERDE VENTURE PARTNERS Novartis Venture Fund

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.